The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sequential salvage chemotherapy and lintuzumab-Ac225 results in deep responses and prolonged survival in adverse risk relapsed/refractory AML and in AML patients that received prior venetoclax therapy.
 
Sameem M. Abedin
Honoraria - Abbvie; Daiichi Sankyo Pharmaceutical; SERVIER
Consulting or Advisory Role - Amgen
Research Funding - Actinium Pharmaceuticals; AltruBio
 
Guru Subramanian Guru Murthy
Honoraria - Cardinal Health; Gilead Sciences; TG therapeutics
Consulting or Advisory Role - Cancer Expert Now; Market Plus; Putnam Associates; Qessential Medical Marketing Research; SmartAnalyst; techspert.io
Research Funding - Xencor
 
Avinash Desai
Employment - Actinium Pharmaceuticals
Leadership - Actinium Pharmaceuticals
Stock and Other Ownership Interests - Actinium Pharmaceuticals
 
Mary Chen
No Relationships to Disclose
 
Ehab L. Atallah
Consulting or Advisory Role - Abbvie/Genentech; Bristol-Myers Squibb; Jazz Pharmaceuticals; Novartis; Pfizer; Syndax; Takeda
Speakers' Bureau - Abbvie; Bristol-Myers Squibb/Celgene; Celgene
Research Funding - Novartis (Inst); Takeda (Inst)